3 US Penny Stocks With Market Caps Over $300M To Watch

The U.S. stock market recently faced a downturn as concerns over China's advancements in artificial intelligence technology weighed heavily on major indices, particularly affecting the tech sector. For investors seeking opportunities beyond large-cap stocks, penny stocks—though an older term—still hold potential for growth and value. These typically smaller or newer companies can offer affordability and growth potential when backed by strong financials, making them worth watching amidst fluctuating market conditions.

Top 10 Penny Stocks In The United States

Click here to see the full list of 713 stocks from our US Penny Stocks screener.

We'll examine a selection from our screener results.

OmniAb (NasdaqGM:OABI)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: OmniAb, Inc. is a biotechnology company focused on the discovery and provision of therapeutic antibody discovery technologies in the United States, with a market cap of approximately $387.24 million.

Operations: The company generates revenue primarily through its Research Services segment, totaling $20.41 million.

Market Cap: $387.24M

OmniAb, Inc., a biotechnology firm, is navigating challenges typical of penny stocks, with recent financials showing a decline in revenue to US$4.17 million for the third quarter of 2024 and increasing net losses. Despite being unprofitable and not expected to turn profitable in the near future, OmniAb benefits from having no debt and sufficient cash runway for over a year based on current free cash flow. The management team is experienced with an average tenure of 2.2 years, though insider selling has been significant recently. Revenue growth is projected at 26.88% annually despite ongoing challenges.

• Click to explore a detailed breakdown of our findings in OmniAb's financial health report.
• Gain insights into OmniAb's future direction by reviewing our growth report.

GoodRx Holdings (NasdaqGS:GDRX)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: GoodRx Holdings, Inc. provides consumers in the United States with tools to compare prescription drug prices and save on purchases, with a market cap of approximately $1.90 billion.

Operations: The company generates revenue primarily from its Healthcare Software segment, which brought in $790.39 million.

Market Cap: $1.9B

GoodRx Holdings, Inc. operates within the healthcare software sector, generating US$790.39 million in revenue, and maintains a market cap of approximately US$1.90 billion. Despite being unprofitable, GoodRx has a positive free cash flow and sufficient cash runway for over three years if maintained at current levels. Recent executive changes include Wendy Barnes as CEO and Scott Wagner's appointment to the board, potentially enhancing leadership stability with their extensive industry experience. The company continues to expand product offerings like GoodRx for Pets and e-commerce solutions, aiming to improve accessibility and affordability of medications across various segments.

• Click here and access our complete financial health analysis report to understand the dynamics of GoodRx Holdings.
• Explore GoodRx Holdings' analyst forecasts in our growth report.

ATRenew (NYSE:RERE)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: ATRenew Inc. operates a platform for pre-owned consumer electronics transactions and services in the People’s Republic of China, with a market cap of approximately $572.85 million.

Operations: The company generates revenue from its Retail - Electronics segment, amounting to CN¥15.35 billion.

Market Cap: $572.85M

ATRenew Inc., with a market cap of approximately $572.85 million, operates in the pre-owned consumer electronics sector in China. Despite being unprofitable, it has reduced losses over the past five years and reported a net income of CN¥17.88 million for Q3 2024, reversing from a loss last year. Its short-term assets significantly exceed liabilities, and it has more cash than total debt. The company forecasts revenue growth between 22.4% to 24.9% year-over-year for Q4 2024 and recently completed a share buyback program worth $20.1 million, indicating confidence in its financial stability and future prospects.

• Dive into the specifics of ATRenew here with our thorough balance sheet health report.
• Understand ATRenew's earnings outlook by examining our growth report.

Key Takeaways

• Access the full spectrum of 713 US Penny Stocks by clicking on this link.
• Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up.
• Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world.

Interested In Other Possibilities?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Jump on the AI train with fast growing tech companies forging a new era of innovation.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com